BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nakamura Y, Sasaki R, Cao X, Wada T, Hamaguchi S, Izumi-Nakaseko H, Ando K, Tanaka H, Takahara A, Sugiyama A. Intravenous anti-influenza drug oseltamivir will not induce torsade de pointes: Evidences from proarrhythmia model and action-potential assay. J Pharmacol Sci 2016;131:72-5. [PMID: 27174864 DOI: 10.1016/j.jphs.2016.04.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Loen V, Vos MA, van der Heyden MAG. The canine chronic atrioventricular block model in cardiovascular preclinical drug research. Br J Pharmacol 2021. [PMID: 33684961 DOI: 10.1111/bph.15436] [Reference Citation Analysis]
2 Schiavone M, Gasperetti A, Gherbesi E, Bergamaschi L, Arosio R, Mitacchione G, Viecca M, Forleo GB. Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19. Cardiac Electrophysiology Clinics 2021. [DOI: 10.1016/j.ccep.2021.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kambayashi R, Izumi-Nakaseko H, Goto A, Tsurudome K, Ohshiro H, Izumi T, Hagiwara-Nagasawa M, Chiba K, Nishiyama R, Oyama S, Nunoi Y, Takei Y, Matsumoto A, Sugiyama A. Translational Studies on Anti-Atrial Fibrillatory Action of Oseltamivir by its in vivo and in vitro Electropharmacological Analyses. Front Pharmacol 2021;12:593021. [PMID: 33995006 DOI: 10.3389/fphar.2021.593021] [Reference Citation Analysis]
4 Frommeyer G, Mittelstedt A, Wolfes J, Ellermann C, Kochhäuser S, Leitz P, Dechering DG, Eckardt L. The anti-influenza drug oseltamivir reduces atrial fibrillation in an experimental whole-heart model. Naunyn Schmiedebergs Arch Pharmacol 2017;390:1155-61. [PMID: 28780600 DOI: 10.1007/s00210-017-1415-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 MacLaren R, Francisco J, Fetters M, Brady J, Kim C, Welker C. Oseltamivir-Associated Bradycardia in Critically Ill Patients. Ann Pharmacother 2021;55:1318-25. [PMID: 33615828 DOI: 10.1177/1060028020988919] [Reference Citation Analysis]
6 Matsukura S, Nakamura Y, Cao X, Wada T, Izumi-Nakaseko H, Ando K, Yamazaki H, Sugiyama A. Characterization of microminipigs as an in vivo experimental model for cardiac safety pharmacology. J Pharmacol Sci 2017;133:103-9. [PMID: 28245963 DOI: 10.1016/j.jphs.2017.02.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]